

Bibliografía

1. Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, *et al.* Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. *Arthritis Rheumatol.* 2015;67:1424-37.
2. Fleischmann R, van Adelsberg J, Lin Y, Castelar-Pinho GD, Brzezicki J, Hrycaj P, *et al.* Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. *Arthritis Rheumatol.* 2017;69:277-90.
3. Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM, *et al.* Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. *Ann Rheum Dis.* 2017;76:840-7.
4. Agencia Española de Medicamentos y Productos Sanitarios. Ficha técnica Kevzara 200 mg solución inyectable en jeringa precargada. [Internet]. AEMPS; 2017. Disponible en https://cima.aemps.es/cima/dochtml/ft/1171196003/FT_1171196003.html
5. Tornero J. Encaje terapéutico de sarilumab en el tratamiento de la artritis reumatoide. *Rheumatol Clin Supl.* 2018;14:70-7.
6. European Medicines Agency. Kevzara. EMA; 2017. Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004254/WC500230070.pdf
7. Genoveses MC, Decktor DL, Parrino J, Boddy A. Effect of Increased Sarilumab Dose on Efficacy and Safety Outcomes in Poorly Responding Rheumatoid Arthritis (RA) Patients: The MOBILITY Study. [Póster]. *Ann Rheum Dis.* 2015;74:727.
8. Burmester GR, Lin Y, St John G, Wang S, Gomez JJ, Maldonado JA, *et al.* Long-term efficacy with 5-year radiographic results and safety of sarilumab in combination with csDMARDs in patients with rheumatoid arthritis. *Ann Rheum Dis.* 2018;77:946-7.
9. Genovese MC, van Adelsberg J, Fan C, Graham NMH, van Hoogstraten H, Parrino J, *et al.* Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes. *Rheumatology (Oxford).* 2018;57:1423-31.
10. Loricera J, Blanco R. Seguridad del sarilumab en pacientes con artritis reumatoide. *Reumatol Clin.* 2018;14:35-41.
11. Emery P, Rondon J, Parrino J, Lin Y, Pena-Rossi C, van Hoogstraten H, *et al.* Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis. *Rheumatology (Oxford).* 2019;58:849-58.
12. Genovese M, van der Heijde D, Lin Y, St John G, Wang S, van Hoogstraten H, *et al.* Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment. *RMD Open.* 2019;5:e000887.
13. Fleischmann R, Genovese M, Lin Y, St John G, van der Heijde D, Wang S, *et al.* Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up. *Rheumatology (Oxford).* 2020;59:292-302.
14. Wright Cross AL, Edwards SW, Moots RJ. Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo. *Rheumatology (Oxford).* 2014;53:1321-31.
15. Gaber T, Hahne M, Strehl C, Hoff P, Dörffel Y, Feist E, *et al.* Disentangling the effects of tocilizumab on neutrophil survival and function. *Immunol Res.* 2016;64:665-76.
16. Summers C, Rankin SM, Condliffe AM, Singh N, Peters AM, Chilvers ER. Neutrophil kinetics in health and disease. *Trends Immunol.* 2010;31:318-24.
17. Curtis J, St John G, Pannucci Mi, Maldonado-Cocco JA. Reversible decreases in absolute neutrophil count (ANC) in rheumatoid arthritis (RA) patients (PTS) on sarilumab: comparison of dose delay and dose decrease vs continued treatment. *Ann Rheum Dis.* 2018;77:946.
18. Tesser J, St. John G, Kimura T, Fiore S, Rischmueller M, Maldonado-Cocco JA, *et al.* Liver Function Test Levels With Sarilumab Treatment in Phase 3 Trials: Analysis by Baseline Liver Function Test (LFT) Level. *Arthritis Rheumatol.* 2018;70.
19. Choy E, Sattar N. Interpreting Lipid Levels in the Context of High-Grade Inflammatory States With a Focus on Rheumatoid Arthritis: A Challenge to Conventional Cardiovascular Risk Actions. *Ann Rheum Dis.* 2009;68:460-9.
20. Charles-Schoeman C, St. John G, Leher H, Kimura T, van Hoogstraten H, Nurmohamed MT, *et al.* The Relationship Between Lipid Profile Changes and Inflammation Across the Phase 3 Sarilumab Rheumatoid Arthritis Developmental Program. *Arthritis Rheumatol.* 2018;70.
21. Choy E, Ganeshalingam K, Semb AG, Szekanecz Z, Nurmohamed M. Actions Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. *Rheumatol (Oxford).* 2014;53:2143-54
22. Genovese M, Burmester G, Hagino O, van Hoogstraten H, Mangan E, *et al.* Effect of sarilumab on glycosylated hemoglobin in patients with rheumatoid arthritis and diabetes. *Ann Rheum Dis.* 2019;78:1128-9.

23. Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, *et al.* EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis.* 2020;0:1-15.
24. Fleischmann R, Selmi C, Gonzalez-Gay MA, van Hoogstraten H, Hagino O, Rajput T, *et al.* Glucocorticoid dose is progressively reduced in patients with RA receiving sarilumab: results from the open-label EXTEND Study. *Arthritis Rheumatol.* 2019;71.
25. Curtis J, Lin Y, Thangavelu K, Stanislav M, St. John G, Gómez- Centeno A, *et al.* Withdrawal of conventional synthetic disease-modifying antirheumatic drugs in sarilumab open-label EXTEND Study: efficacy and safety analysis. *Ann Rheum Dis.* 2019;78:702-3.
26. Wells A, Parrino J, Mangan E, Paccaly A, Lin Y, Xu C, *et al.* Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs. *Rheumatol Ther.* 2019;6:339-52.
27. Genovese M, Fay J, Parrino J, Beyer D, Iglesias-Rodriguez M, Graham N, *et al.* Sarilumab Dose Reduction in an Open-label extension study in RA patients. *Arthritis Rheumatol.* 2016;68.
28. Genovese M, Decktor D, Parrino J, Boddy A, Graham N. Effect of Increased Sarilumab Dose on Efficacy and Safety Outcomes in Poorly Responding RA Patients. *Ann Rheum Dis.* 2015;74:727.